Immunosuppressive effects of pteridine derivatives

1. A poly-substituted pteridinedione (lumazine), being selected from the group consisting of:

1,3-dimethyl-6-[(E)-2-(pyrid-3-yl)vinyl]lumazine,

1,3-dimethyl-6-[(E)-2-(pyrid-4-yl)vinyl]lumazine,

6-(1,2-dibromo-2-phenylethyl)-1,3-dimethyllumazine,

1,3-dimethyl-6-[(E)-4-(phenyl)butadienyl]lumazine,

6-(1,2-dibromo-2-(methoxycarbonyl)ethyl)-1,3-dimethyllumazine,

6-(2-bromo-2-methoxycarbonyl-ethenyl)-1,3-dimethyllumazine,

6-[(2-acetyl-2-ethoxycarbonyl)acetyl]-1,3-dimethyllumazine,

6-[2,2-(diethoxycarbonyl)acetyl]-1,3-dimethyllumazine,

6-(1-methoxy-2-methoxycarbonyl)ethenyl)-1,3-dimethyllumazine,

1,3-dimethyl-6-[(2-nitro)ethenyl]lumazine,

6-[(1-hydroxy-2-nitro)ethyl]-1,3-dimethyllumazine,

6-[(1-ethylthio-2-nitro)ethyl]-1,3-dimethyllumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-2-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-3-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-4-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-4-(phenyl)butadienyl]lumazine,

7-1,2-dibromo-2-(methoxycarbonyl)ethyl)-1,3-dimethyllumazine,

7-[(E)-2-methoxycarbonylethenyl]lumazine,

7-(1,2-dibromo-2-phenylethyl)-1,3-dimethyllumazine,

7-(1-bromo-2-phenyl)ethenyl-1,3-dimethyllumazine,

1,3-dimethyl-7-(E)-styryllumazine,

1,3-dimethyl-6-phenyl-7-mercaptolumazine,

7-methoxy-1,3-dimethyl-6-phenyllumazine,

7-chioro-1,3-dimethyl-6-phenylluniazine,

6-benzoyl-7,8-dihydro-1,3-dimethyl-7-(4-methoxyphenyl)lumazine,

6-benzoyl-1,3-dimethyl-7-(4-methoxyphenyl)lumazine,

6-benzoyl-7,8-dihydro-1,3-dimethyl-7-phenyllumazine,

6-benzoyl-1,3-dimethyl-7-phenyllumazine,

7-methoxy-1,3-dimethyl-6-styryllumazine,

7-hydroxy-1,6-diphenyllumazine,

7-hydroxy-6-phenyl-1,3-di-n-propyllumazine,

6-formyl-7-hydroxy-1,3-dimethyl-lumazine,

6-hydroxy-7-formyl-1,3-dimethyl-lumazine,

6-cyano-7-chloro-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-chloro-1,3-dimethyl-lumazine,

6-(1,3-dioxolanyl)-7-chloro-1,3-dimethyl-lumazine,

6-dichloromethyl-7-chloro-1,3-dimethyl-lumazine,

6-chloro-7-cyano-1,3-dimethyl-lumazine,

6-cyano-7-isobutylamino-1,3-dimethyl-lumazine,

6-cyano-7-benzylamino-1,3-dimethyl-lumazine,

6-cyano-7-acetenylamino-1,3-dimethyl-lumazine,

6-cyano-7-cyclohexylamino-1,3-dimethyl-lumazine,

6-cyano-7-dibutylamino-1,3-dimethyl-lumazine,

6-cyano-7-imidazolyl-1,3-dimethyl-lumazine,

6-cyano-7-mercaptoisopropyl-1,3-dimethyl-lumazine,

6-cyano-7-mercaptobenzyl-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-n-butylamino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-neopentylamino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-(2-propenylamino)-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-piperidinyl-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-phenylhydrazino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-mercaptoethyl-1,3-dimethyl-lumazine,

6-formyl-7-isopropylamino-1,3-dimethyl-lumazine,

6-formyl-7-hydroxyethylamino-1,3-dimethyl-lumazine,

6-formyl-7-(1-azacycloheptyl)-1,3-dimethyl-lumazine,

6-formyl-7-thiomorpholino-1,3-dimethyl-lumazine,

6-formyl-7-cyclopropylamino-1,3-dimethyl-lumazine,

6-dichloromethyl-7-mercaptobenzyl-1,3-dimethyl-lumazine,

6-dichloromethyl-7-ethylmercaptoacetate-1,3-dimethyl-lumazine,

6-benzylamino-1,3,7-trimethyl-lumazine,

6-pyrrolidinyl-1,3,7-trimethyl-lumazine,

6-chloro-7-piperidyl-1,3-diimethyl-lumazine,

7-(2-phenylethenyl)-1,3,6-trimethyl-lumazine,

6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyllumazine,

6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyllumazine,

6-[2-phenylethenyl]-1,3-dimethyllumazine,

6-[2-(p-trifluoromethoxyphenyl)ethenyl]-1,3-dimethyllumazine,

6-cyano-7-ethylmercaptoacetate-1,3-dimethyllumazine,

3-methyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-phenyl-7-hydroxy-lumazine,

1-methyl-6-(4′-methoxyphenyl)-7-hydroxy-lumazine,

1-methyl-6-(4′-methylphenyl)-7-hydroxy-lumazine,

1,6-diphenyl-7-hydroxy-lumazine,

1-benzyl-6-phenyl-7-hydroxy-lumazine,

1-methyl-6-(3′,4′-dimethoxyphenyl)-7-hydroxy-lumazine,

1-methyl-6-(4′-chlorophenyl)-7-hydroxy-lumazine,

1-methyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-(4′-methoxyphenyl)-7-chloro-lumazine,

1-methyl-6-(4′-methylphenyl)-7-chloro-lumazine,

1,6-diphenyl-7-chloro-lumazine,

1-benzyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-(3′,4′-dimethoxyphenyl)-7-chloro-lumazine,

1-methyl-6-(4′-chlorophenyl)-7-chloro-lumazine,

1,3-dimethyl-6-phenyl-7-phenoxylumazine,

1,3-dimethyl-6-phenyl-7-piperidinolumazine,

1,3-dimethyl-6-phenyl-7-morpholinolumazine,

1,3-dimethyl-6-phenyl-7-( 4′-N-acetyl)piperazinolumazine, and

1,3-dimethyl-6-phenyl-7-isopropylaminolumazine.

2. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and one or more poly-substituted pteridinediones (lumazines), selected from the group consisting of:

1,3-dimethyl-6-[(E)-2-(pyrid-3-yl)vinyl]lumazine,

1,3-dimethyl-6-[(E)-2-(pyrid-4-yl)vinyl]lumazine,

6-(1,2-dibromo-2-phenylethyl)-1,3-dimethyllumazine,

1,3-dimethyl-6-[(E)-4-(phenyl)butadienyl]lumazine,

6-(1,2-dibromo-2-(methoxycarbonyl)ethyl)-1,3-dimethyllumazine,

6-(2-bromo-2-methoxycarbonyl-ethenyl)-1,3-dimethyllumazine,

6-[(2-acetyl-2-ethoxycarbonyl)acetyl]-1,3-dimethyllumazine,

6-[2,2-(diethoxycarbonyl)acetyl]-1,3-dimethyllumazine,

6-(1-methoxy-2-methoxycarbonyl)ethenyl)-1,3-dimethyllumazine,

1,3-dimethyl-6-[(2-nitro)ethenyl]lumazine,

6-[(1-hydroxy-2-nitro)ethyl]-1,3-dimethyllumazine,

6-[(1-ethylthio-2-nitro)ethyl]-1,3-dimethyllumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-2-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-3-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-2-(pyrid-4-yl)vinyl]lumazine,

1,3-dimethyl-7-[(E)-4-(phenyl)butadienyl]lumazine,

7-[1,2-dibromo-2-(methoxycarbonyl)ethyl)-1,3-dimethyllumazine,

7-[(E)-2-methoxycarbonylethenyl]lumazine,

7-(1,2-dibromo-2-phenylethyl)-1,3-dimethyllumazine,

7-(1-bromo-2-phenyl)ethenyl-1,3-dimethyllumazine,

1,3-dimethyl-6-(E)-styryllumazine,

1,3-dimethyl-7-(E)-styryllumazine,

1,3-dimethyl-6-phenyl-7-mercaptolumazine,

7-methoxy-1,3-dimethyl-6-phenyllumazine,

7-chloro-1,3-dimethyl-6-phenyllumazine,

6-benzoyl-7,8-dihydro-1,3-dimethyl-7-(4-methoxyphenyl)lumazine,

6-benzoyl-1,3-dimethyl-7-(4-methoxyphenyl)lumazine,

6-benzoyl-7,8-dihydro-1,3-dimethyl-7-phenyllumazine,

6-benzoyl-1,3-dimethyl-7-phenyllumazine,

7-methoxy-1,3-dimethyl-6-styryllumazine,

7-hydroxy-1,6-diphenyllumazine,

7-hydroxy-6-phenyl-1,3-di-n-propyllumazine,

6-formyl-7-hydroxy-1,3-dimethyl-lumazine,

6-hydroxy-7-formyl-1,3-dimethyl-lumazine,

6-cyano-7-chloro-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-chloro-1,3-dimethyl-lumazine,

6-(1,3-dioxolanyl)-7-chloro-1,3-dimethyl-lumazine,

6-dichloromethyl-7-chloro-1,3-dimethyl-lumazine,

6-chloro-7-cyano-1,3-dimethyl-lumazine,

6-cyano-7-isobutylamino-1,3-dimethyl-lumazine,

6-cyano-7-benzylamino-1,3-dimethyl-lumazine,

6-cyano-7-acetenylamino-1,3-dimethyl-lumazine,

6-cyano-7-cyclohexylamino-1,3-dimethyl-lumazine,

6-cyano-7-dibutylamino-1,3-dimethyl-lumazine,

6-cyano-7-imidazolyl-1,3-dimethyl-lumazine,

6-cyano-7-mercaptoisopropyl-1,3-dimethyl-lumazine,

6-cyano-7-mercaptobenzyl-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-n-butylamino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-neopentylamino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-(2-propenylamino)-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-piperidinyl-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-phenylhydrazino-1,3-dimethyl-lumazine,

6-ethylcarboxylate-7-mercaptoethyl-1,3-dimethyl-lumazine,

6-formyl-7-isopropylamino-1,3-dimethyl-lumazine,

6-formyl-7-hydroxyethylamino-1,3-dimethyl-lumazine,

6-formyl-7-(1-azacycloheptyl)-1,3-dimethyl-lumazine,

6-formyl-7-thiomorpholino-1,3-dimethyl-lumazine,

6-formyl-7-cyclopropylamino-1,3-dimethyl-lumazine,

6-dichloromethyl-7-mercaptobenzyl-1,3-dimethyl-lumazine,

6-dichloromethyl-7-ethylmercaptoacetate-1,3-dimethyl-lumazine,

6-benzylamino-1,3,7-trimethyl-lumazine,

6-pyrrolidinyl-1,3,7-trimethyl-lumazine,

6-chloro-7-piperidyl-1,3-diimethyl-lumazine,

7-(2-phenylethenyl)-1,3,6-trimethyl-lumazine,

6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyllumazine,

6-[2-(p-trifluoromethylphenyl)ethenyl]-1,3-dimethyllumazine,

6-[2-phenylethenyl]-1,3-dimethyllumazine,

6-[2-(p-trifluoromethoxyphenyl)ethenyl]-1,3-dimethyllumazine,

6-cyano-7-ethymercaptoacetate-1,3-dimethyllumazine,

3-methyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-phenyl-7-hydroxy-lumazine,

1-methyl-6-(4′-methoxyphenyl)-7-hydroxy-lumazine,

1-methyl-6-(4′-methylphenyl)-7-hydroxy-lumazine,

1,6-diphenyl-7-hydroxy-lumazine,

1-benzyl-6-phenyl-7-hydroxy-lumazine,

1-methyl-6-(3′,4′-dimethoxyphenyl)-7-hydroxy-lumazine,

1-methyl-6-(4′-chlorophenyl)-7-hydroxy-lumazine,

1-methyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-(4′-methoxyphenyl)-7-chloro-lumazine,

1-methyl-6-(4′-methylphenyl)-7-chloro-lumazine,

1,6-diphenyl-7-chloro-lumazine,

1-benzyl-6-phenyl-7-chloro-lumazine,

1-methyl-6-(3′,4′-dimethoxyphenyl)-7-chloro-lumazine,

1-methyl- 6-( 4′-chlorophenyl)-7-chloro-lumazine,

1,3-dimethyl-6-phenyl-7-phenoxylumazine,

1,3-dimethyl-6-phenyl-7-piperidinolumazine,

1,3-dimethyl-6-phenyl-7-morpholinolumazine,

1,3-dimethyl-6-phenyl-7-( 4′-N-acetyl)piperazinolumazine, and

1,3-dimethyl-6-phenyl-7-isopropylaminolumazine.

3. A pharmaceutical composition according to claim 2 , further comprising one or more biologically-active drugs selected from the group consisting of immunosuppressant and/or immunomodulator drugs, antineoplastic drugs, and antiviral agents.

4. A pharmaceutical composition according to 2 , further comprising one or more immunosuppressant drugs selected from the group consisting of cyclosporin A; substituted xanthines, e.g. pentoxyfylline; tacrolimus; rapamycin and derivatives thereof, leflunomide or an active metabolite or an analog thereof; mycophenolic acid and salts thereof; adrenocortical steroids, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, chloroquine, hydroxychloroquine and monoclonal antibodies with immunosuppressive properties.

5. A pharmaceutical composition according to 2 , further comprising one or more immunomodulator drugs selected from the group consisting of acemannan, amiprilose, bucillamine, ditiocarb sodium, imiquimod, Inosine Pranobex, interferon-β, interferon-γ, lentinan, levamisole, pidotimod, romurtide, platonin, procodazole, propagermanium, thymomodulin, thymopentin and ubenimex.

6. A pharmaceutical composition according to claim 2 , further comprising one or more antineoplastic drugs selected from the group consisting of alkaloids, alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, antibiotics, antimetabolites, folio acid analogs, purine analogs, pyrimidine analogs, enzymes, interferon and platinum complexes.

7. A pharmaceutical composition according to claim 2 , further comprising one or more antiviral agents selected from the group consisting of retroviral enzyme inhibitors, HIV-1 IN inhibitors, nucleoside reverse transcriptase inhibitors, zidovudine, lamivudine, didanosme, stavudine, zalcitabine, non-nucleoside reverse transcriptase inhibitors, nevirapine, delavirdine, other reverse transcriptase inhibitors, foscamet sodium, HIV-1 protease inhibitors, saquinavir, ritonavir, indinavir, nelfinavir, acyclovir, cidofovir, cytarabine, edoxudine, famciclovir, floxuridine, ganciclovir, idoxuridine, penciclovir, sorivudine, trifluridine, valaciclovir, vidarabine, kethoxal, methisazone, moroxydine, podophyllotoxin, ribavirine, rimantadine, stallimycine, statolon, tromantadine and xenazoic acid.

8. A pharmaceutical composition according to claim 2 , wherein said one or more pharmaceutically acceptable carriers are selected from the group consisting of wetting agents, dispersing agents, adhesives, surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents, isotonic agents, azo dyes; organic and inorganic pigments; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants; preservatives; sequestering; flavoring agents; bulking agents and densification agents.